Table 2. Meibomian gland dysfunction scores before and after treatment.

	BL	FU1	FU2	p (BL–FU2)	p (BL–FU1)	p (FU1–FU2)
Group 1
BUT	4.02 ± 1.75	6.02 ± 2.32	7.95 ± 2.54	0.004	0.023	0.002
Oxford Gr	1.42 ± 0.59	0.72 ± 0.65	0.45 ± 0.60	<0.001	<0.001	0.042
MGE	1.97 ± 0.77	1.56 ± 0.69	1.42 ± 0.75	0.001	<0.001	0.388
MQ	2.08 ± 0.61	0.20 ± 0.09	0.17 ± 0.09	<0.001	<0.001	0.645
OSDI	58.86 ± 19.88	41.23 ± 26.46	27.75 ± 11.55	<0.001	0.040	0.002
Group 2
BUT	4.60 ± 1.32	4.86 ± 2.11	7.41 ± 3.37	0.005	0.029	0.007
Oxford Gr	1.50 ± 0.67	0.80 ± 0.76	0.38 ± 0.49	<0.001	<0.001	0.030
MGE	1.93 ± 0.95	1.56 ± 0.79	1.50 ± 0.51	0.032	<0.001	0.333
MQ	2.11 ± 0.50	0.19 ± 0.10	0.19 ± 0.06	<0.001	<0.001	0.333
OSDI	64.92 ± 21.88	39.20 ± 15.42	26.55 ± 13.95	<0.001	<0.001	<0.001

BL = baseline; FU1 (first follow-up) = 2 weeks after the second treatment session; FU2 (second follow-up) = 2 weeks after the fourth treatment session; BUT = tear film break up time; MGE = Meibomian gland expressibility score; MQ = meibum quality score; OSDI = Ocular Surface Disease Index.

p-values were obtained using Wilcoxon signed-rank test.